We are looking for a Chief Medical Officer will play a pivotal role in shaping the clinical strategy and ensuring the highest standards of medical excellence. You will lead and oversee the implementation of prospective clinical validation of innovative cancer diagnostic tests, driving the development and implementation of advanced diagnostic solutions to transform breast cancer care. You will also be in charge of direct communication with breast cancer patients and their oncologists.
Direct communication with patients and oncologists:
Prospective clinical validation:
Clinical Strategy Development:
Key Opinion Leader Engagement:
Medical Affairs and Education:
Team Leadership and Development:
Cross Functional Collaboration:
Interested candidates are invited to submit their resume, cover letter, and any supporting materials to[career@multiplexdx.com]. Please include "Chief Medical Officer Application - MultiplexDX" in the subject line.
MultiplexDX is a cutting-edge cancer diagnostic company revolutionizing personalized medicine through innovative molecular diagnostics. Our mission is to improve patient outcomes by providing accurate cancer diagnoses and provide prognostic and predictive treatment signatures, enabling physicians to tailor treatments for optimal results.
Peter Kilian
COO
Ilkovičova 8
84104 Bratislava, Slovakia
career@multiplexdx.com
www.multiplexdx.com
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter